Celldex Therapeutics Inc Total Liabilities
Celldex Therapeutics Inc total liabilities. Based on the latest financial reports, Celldex Therapeutics Inc (CLDX) has total liabilities worth $55.03 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See CLDX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Celldex Therapeutics Inc (1985–2025)
Total liabilities of Celldex Therapeutics Inc from 1985 to 2025. This chart illustrates how Celldex Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Celldex Therapeutics Inc (CLDX) asset resilience to evaluate the company's liquid asset resilience ratio.
Celldex Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Celldex Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tongling Jingd
SHG:600577
|
China | CN¥10.25 Billion |
|
BGI Genomics Co Ltd
SHE:300676
|
China | CN¥2.81 Billion |
|
Northern Oil & Gas Inc
NYSE:NOG
|
USA | $3.83 Billion |
|
Banque Cantonale de Geneve
SW:BCGE
|
Switzerland | CHF33.00 Billion |
|
Hyundai Steel
KO:004020
|
Korea | ₩15.40 Trillion |
|
Webull Corp
NASDAQ:BULL
|
USA | $2.86 Billion |
|
Dynex Capital Inc
NYSE:DX
|
USA | $21.62 Billion |
|
ACC Limited
NSE:ACC
|
India | Rs69.71 Billion |
Liability Composition Analysis (1985–2025)
This chart breaks down Celldex Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Celldex Therapeutics Inc.
Liquidity & Leverage Metrics
Celldex Therapeutics Inc Total Liabilities Ratios Explained
Celldex Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celldex Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celldex Therapeutics Inc (1985–2025)
The table below shows the annual total liabilities of Celldex Therapeutics Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $55.82 Million | +23.12% |
| 2024-12-31 | $45.34 Million | +24.36% |
| 2023-12-31 | $36.46 Million | +37.41% |
| 2022-12-31 | $26.53 Million | +5.37% |
| 2021-12-31 | $25.18 Million | -4.92% |
| 2020-12-31 | $26.48 Million | -8.39% |
| 2019-12-31 | $28.91 Million | -8.95% |
| 2018-12-31 | $31.75 Million | -59.94% |
| 2017-12-31 | $79.25 Million | -32.79% |
| 2016-12-31 | $117.93 Million | +148.38% |
| 2015-12-31 | $47.48 Million | +30.60% |
| 2014-12-31 | $36.35 Million | +33.16% |
| 2013-12-31 | $27.30 Million | -8.29% |
| 2012-12-31 | $29.77 Million | +1.69% |
| 2011-12-31 | $29.27 Million | -15.61% |
| 2010-12-31 | $34.69 Million | -47.91% |
| 2009-12-31 | $66.60 Million | +28.92% |
| 2008-12-31 | $51.66 Million | -8.88% |
| 2007-12-31 | $56.69 Million | -4.43% |
| 2006-12-31 | $59.32 Million | +281.16% |
| 2005-12-31 | $15.56 Million | +110.43% |
| 2004-12-31 | $7.40 Million | +118.46% |
| 2003-12-31 | $3.39 Million | -12.94% |
| 2002-12-31 | $3.89 Million | -52.67% |
| 2001-12-31 | $8.22 Million | -14.69% |
| 2000-12-31 | $9.63 Million | +289.97% |
| 1999-12-31 | $2.47 Million | -36.67% |
| 1998-12-31 | $3.90 Million | +11.43% |
| 1997-12-31 | $3.50 Million | +118.75% |
| 1996-12-31 | $1.60 Million | -36.00% |
| 1995-12-31 | $2.50 Million | -19.35% |
| 1994-12-31 | $3.10 Million | -22.50% |
| 1993-12-31 | $4.00 Million | +66.67% |
| 1992-12-31 | $2.40 Million | -14.29% |
| 1991-12-31 | $2.80 Million | 0.00% |
| 1990-12-31 | $2.80 Million | +12.00% |
| 1989-12-31 | $2.50 Million | -47.92% |
| 1988-12-31 | $4.80 Million | +29.73% |
| 1987-12-31 | $3.70 Million | -11.90% |
| 1986-12-31 | $4.20 Million | -26.32% |
| 1985-12-31 | $5.70 Million | -- |
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzo… Read more